• Citigroup (NYSE:C) understated risk-weighted assets by about $35 billion at its European trading unit after using an internal risk model without regulatory approval.
  • The bank injected additional capital into the subsidiary to restore buffers, though it says regulatory minimums were never breached and main banking operations were unaffected.
  • The incident adds scrutiny to CEO Jane Fraser's regulatory overhaul, which has already faced consent orders and hundreds of millions in fines.

Citigroup incorrectly recorded certain trades at its European trading unit, understating risk-weighted assets by approximately $35 billion, according to people familiar with the matter. The discrepancy represented roughly 2.7% of Citi's $1.2 trillion total risk-weighted assets, and the bank has injected additional capital into the subsidiary to restore regulatory buffers.

The issue, identified and resolved this summer, stemmed from Citi's UK securities unit applying an internal risk model to trades for which regulators had not approved that model. Recalculating the transactions using a standard risk model substantially increased risk-weighted assets, the regulatory measure used to determine required capital. The bank confirmed no impact on its main banking operations and said it remained above regulatory minimums throughout.

The $35 billion figure does not represent a trading loss. Rather, it reflects a capital-modeling and controls failure that required additional equity at the affected subsidiary even though the underlying trades did not change. The size of the capital injection was not disclosed.

Citi's latest quarterly results, filed with the SEC in October, showed revenue of $23.8 billion, up 8% year over year, and net income of $5.2 billion, up 40%. Its common equity tier 1 capital ratio stood at 12.8%, unchanged from the previous quarter. The prior-year comparison included a $726 million goodwill impairment tied to Banamex, making the reported earnings growth look stronger.

The incident adds to Citi's recent history of operational and compliance issues. In 2020, the Federal Reserve and the Office of the Comptroller of the Currency fined the bank $400 million for risk-management and data-governance deficiencies. In 2024, regulators imposed an additional $136 million in penalties over insufficient progress. Reuters (NASDAQ:TRI) reported in October that Citi was preparing comprehensive audit material to seek removal of the consent orders, with a potential submission before year-end or in the first quarter.

"What institutional investors like us are really focused on is regulatory stability," said a person familiar with the bank's thinking, speaking on condition of anonymity. Citi declined to comment on the record beyond its statement that the issue was resolved and that regulatory minimums were never breached.

Analysts have viewed the lifting of the consent orders as a potential catalyst for freeing resources and supporting Citi's shares. The latest disclosure creates uncertainty around that prospect and raises questions about whether substantial remediation spending has produced durable controls.

The bank is also in the midst of simplifying its business portfolio. It has integrated retail banking into Wealth, combined its principal US card businesses into US Consumer Cards, and divested 49% of Banamex by the third quarter, with deconsolidation expected in 2027. CEO Jane Fraser remains chair and CEO, while Gonzalo Luchetti took over as CFO in March 2026.

A close industry precedent is Metro Bank (LSE:MTRO)'s 2019 correction of approximately £900 million in risk-weighted assets after incorrectly weighting commercial loans. The Prudential Regulation Authority later fined Metro £5.376 million for regulatory-reporting and control failures. Importantly, Metro remained compliant with its capital requirement, underscoring that inaccurate capital reporting can warrant enforcement even without a minimum-capital breach.

Citi's statement that group entities were unaffected is reassuring, but it remains the bank's account rather than a published regulatory conclusion. The exact identity of the subsidiary, the size of the capital injection, and when the error began all remain undisclosed. Further supervisory scrutiny or additional remediation is possible, though no new fine or formal enforcement action was announced.